New quality productivity is a new concept first proposed by JinPing Xi during his investigation in Heilongjiang in September 2023, emphasizing that "integrating scientific and technological innovation resources to lead the development of strategic new industries and future industries". The concept is of great significance for achieving high-level scientific and technological self-reliance, leading high-quality development, and promoting Chinese-style modernization.
Biomedicine is not only a strategic emerging industry, but also a livelihood industry that protects people’s health. Exploring its innovative attributes such as high-tech, high efficiency and high quality is of great values, and is an important focus to promote the development and form the new quality productivity of the industry.
In April 2024, a delegation composed of many official authoritative media, including People's Daily, Xinhua News Agency, Economic Daily, and China Foreign Literature Administration, entered Daxing Biomedical Industry Base to explore new quality productivity from a front-line perspective by visiting innovative biomedical enterprises. As the main land for the development of Beijing's medical and health industry, Daxing Biomedical Industry Base has actively introduced the cross-integration projects of medical and health, artificial intelligence, and big data, promoting the cutting-edge technologies of life and health in the industry base. As one of the representative enterprises in the industry base, Hotgen Biotech has realized the in vitro diagnosis and innovative drug research and development.
Through the interview with Mr. Lin Changqing, chairman of Hotgen Biotech & Sungen Biomedical, Professor Sun Zhiwei, Manager of Sungen Biomedical, and Director Xu Lida of X-Gen AI New Drug Discovery and Design Research Center, the media delegation learned that the AI technology accelerated the R&D of FIC antibodies, and explored the new quality productivity of the biomedical industry.
Beijing Sungen Biomedical Technology Co., LTD. (referred to as "Sungen Biomedical") is innovation-driven, and committed to the development of original (FIC, First in class) antibody therapeutics. The "X-Gen AI New Drug Discovery and Design Research Center" deeply integrated artificial intelligence algorithms with biopharmaceutical technology, accelerating the new drug discovery and design process to explore more innovative breakthroughs for the healthcare industry.
 | Professor Sun Zhiwei |
| General Manager, Chief scientist of Sungen Biomedical | |
| Outstanding scientific and technological workers of Daxing District, Beijing | |
| New national leading talents of Daxing District, Beijing |
"Sungen Biomedical focuses on the research and development of the world's First FIC antibody therapeutics, and the introduction of artificial intelligence technology will effectively shorten the total research and development time and effectively improve the accuracy of new target discovery."
Taking the AI integrated dry and wet antibody drug laboratory of Sungen Biomedical as an example, antibody molecules with a 10-fold increase in affinity can be obtained within two months by the affinity maturity platform of dry and wet combination, with the optimization and screening by AI models.
Enabled by AI technology, Sungen Biomedical has built a pipeline of innovative antibody drugs for chronic diseases, and some projects have been double-registered in China and the United States. Some pipelines have entered the drug evaluation stage.
Recently, Beijing Municipal Medical Security Bureau and nine other departments jointly launched the "Several Measures for Beijing to Support the High-quality Development of Innovative Medicine. (2024)", mobilizing multiple departments to jointly work to form a multidimensional support for the development of innovative medicine industry. It is believed that with the support of national macro-control, favorable industrial policies, and innovative technologies, the field of biomedical innovation will experience a new round of leap forward."
 | Professor Xu Lida |
| X-Gen AI New Drug Discovery and Design Research Center, Director | |
| Beijing Daxing District Outstanding Young Talents |
X-Gen AI New Drug Discovery and Design Research Center, is focusing on the exploration of new target discovery, molecular design of antibody drugs and nucleic acid drugs, drug formation prediction and other important directions for pharmaceutical companies. In the practice of AI-assisted antibody drug discovery, the "double Ten Law" has been effectively broken by building an innovative "affinity maturation" and "de novo design" algorithm process. Recently, our team's first academic work has been published in PLOS Computational Biology, a highly influential journal in the field of bioinformatics and computational biology. The exploration of AI-based technology in the field of innovative drug research requires technical and professional supports, with more time and patience, and its value and significance will be far-reaching.
To actively explore the field of biomedical innovation，Sungen Biomedical has taken a leading step in the direction of "artificial intelligence + biomedicine". With the in-depth application and exploration of artificial intelligence (AI) in the direction of antibody drug research and development, Sungen Biomedical will further enrich and strengthen the originality and scientific innovations.
Updated: Jul 24, 2024
